Skip to main content

Advertisement

Table 1 A subset of CRTC1-MAML2 target gene candidates is shown

From: Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells

Gene symbol Gene title H3118 Fusion & MAML2 KD/Control HSY MAML2 KD/Control Subcelluar localization Type(s) Drug(s) Biomarker application(s)
LINC00473a long Intergenlc non-protein coding RNA 473 −37.12 −1.03 Unknown other   
Plasma transmembrane
DMBT1a deleted in malignant brain tumors 1 −35.73 1.16 Membrane receptor   
secreted
STC1a stanniocalcin 1 −21.74 1.03 Extracellular glycoprotein   Diagnosis
PDE4B phosphodiesterase 4B, cAMP-specific −8.41 1.09 Cytoplasm enzyme dyphylline, nitroglycerin  
transcription
RUNX3 runt-related transcription factor 3 −4.88 1.03 Nucleus regulator   Diagnosis
Prognosis
PTGS1a prostaglandin-endoperoxide synthase 1 −3.89 1.31 Cytoplasm enzyme acetaminophen, aspirin Progression
Prognosis
PDE4D phosphodiesterase 4D, cAMP-specific −2.93 1.05 Cytoplasm enzyme dyphylline, nitroglycerin Prognosis
Diagnosis
Efficacy
CA9a carbonic anhydrase IX −2.77 1.2 Nucleus enzyme CG250, Methazolamide Tazarotene Prognosis
Diagnosis
ODC1 ornithine decarboxylase 1 −2.54 −1.06 Cytoplasm enzyme Eflornithine Efficacy
AP-12009
TGFB2a transforming growth factor, beta 2 −2.48 1.21 Extracellular growth factor Lerdelimumab Efficacy
Diagnosis
AREGa Amphiregulin −2.23 1.11 Extracellular growth factor Cetuximab, gefitinib Efficacy
Prognosis
TYMSa thymidylate synthetase −2.1 −1.03 Nucleus enzyme Flucytosine, 5-fluorouracil Diagnosis
Efficacy
Prognosis
CDK6 cvclin-deDendent kinase 6 −2.07 1.02 Nucleus kinase PD-0332991 Proanosis
flavopiridol
  1. The fold changes of gene expression were shown for fusion-positive MEC H3118 cells with fusion/MAML2 knockdown (KD), and fusion-negative HSY cells with MAML2 KD
  2. a Genes down-regulated in H3118 cells with CREB KD